Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Moodys
Cipla
Federal Trade Commission
Cantor Fitzgerald

Generated: April 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,296,782

« Back to Dashboard

Which drugs does patent 9,296,782 protect, and when does it expire?

Patent 9,296,782 protects VOSEVI and is included in one NDA.

This patent has sixty-three patent family members in thirty-eight countries.

Summary for Patent: 9,296,782
Title:Inhibitors of hepatitis C virus
Abstract: Compounds of Formula I are disclosed ##STR00001## As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
Inventor(s): Bjornson; Kyla (San Lorenzo, CA), Canales; Eda (San Mateo, CA), Cottell; Jeromy J. (Redwood City, CA), Karki; Kapil Kumar (Foster City, CA), Katana; Ashley Anne (San Mateo, CA), Kato; Darryl (San Francisco, CA), Kobayashi; Tetsuya (Sunnyvale, CA), Link; John O. (San Francisco, CA), Martinez; Ruben (South San Francisco, CA), Phillips; Barton W. (San Mateo, CA), Pyun; Hyung-Jung (Fremont, CA), Sangi; Michael (Oakland, CA), Schrier; Adam James (Redwood City, CA), Siegel; Dustin (Foster City, CA), Taylor; James G. (San Mateo, CA), Tran; Chinh Viet (San Diego, CA), Trejo Martin; Teresa Alejandra (Union City, CA), Vivian; Randall W. (San Mateo, CA), Yang; Zheng-Yu (Palo Alto, CA), Zablocki; Jeff (Los Altos, CA), Zipfel; Sheila (San Mateo, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:13/934,090
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,296,782
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,296,782

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,296,782

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 3903 ➤ Try a Free Trial
Argentina 091661 ➤ Try a Free Trial
Australia 2013286729 ➤ Try a Free Trial
Australia 2016200201 ➤ Try a Free Trial
Australia 2016200670 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Julphar
Daiichi Sankyo
Express Scripts
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.